The Wildcat Philanthropic Seed Fund, launched by Tech Launch Arizona in 2023, has raised nearly 60% of its $5 million initial goal and made its first investments in three startups commercializing University of Arizona innovations. The fund addresses the critical “valley of death”—the period shortly after a venture launches when failure risk is highest.
CarbeniumTec: Energy Storage Innovation
CarbeniumTec, launched in 2022, was founded to commercialize a new organic-based reduction-oxidation battery that reimagines electricity storage. Based on research by associate professor Thomas Gianetti and postdoctoral researcher Joules Moutet, the company develops a sustainable, metal-free, and environmentally friendly solution for large-scale, longer-term energy storage. While current lithium-ion batteries are suited for four to six hours of storage, renewable implementation requires solutions storing electricity for eight to twelve hours. The leadership team includes Gianetti as CEO, Moutet as CTO, and Tucson entrepreneur Philip Lacovara as COO. Over the next two years, the team plans to further develop the product and obtain required certifications to begin manufacturing and selling to customers.
LifeSpan Digital Health: Physician Wellness
LifeSpan Digital Health addresses healthcare professional burnout through emPower+, a science-based, real-time software platform supporting physician and nurse wellness. Based on over twenty years of career research by Dr. Samuel Keim, professor of emergency medicine at the College of Medicine, the platform was developed after Keim observed that while some residents thrive in stressful environments, others struggle. More than 50% of physicians meet the clinical definition of burnout, rising to 63% in emergency medicine. Since forming, LifeSpan has launched a minimum viable product and secured pilot programs at five institutions, including one of the largest medical centers in the world.
UGenome AI: Genomic Medicine
UGenome AI launched in 2023 after licensing a novel genomic platform developed by doctoral student Adam Grant. The platform precisely targets therapies based on patient genetic makeup, providing medication response, food, and longevity information to identify ideal treatment options. The company’s mission is to accelerate genomic medicine benefits for patients and healthcare professionals through clinically actionable insights.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://news.arizona.edu/news/evergreen-fund-fueled-philanthropic-gifts-invests-startups-commercializing-ua-innovations